Back to search

Article

New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirin

2024-07-03

Abstract excerpt

<h4>Background: </h4> : Several studies have resulted in controversial data about the recurrence or new incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C who were treated with direct-acting antivirals (DAAs).   <h4>Aim: </h4> This observational study aimed to assess the occurrence rate of HCC in patients who developed a sustained virological response (SVR). METHOD :  A six-month prospectiv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
45ff4927-c2ff-5617-b795-19ce8b0f4f88
DOI
10.12688/f1000research.73076.3
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirinDOI 10.12688/f1000research.73076.3
The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.Semantic proximity
Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.Semantic proximity
Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.Semantic proximity
DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C DO NOT AFFECT THE RISK OF DEVELOPMENT OR THE OUTCOME OF HEPATOCELLULAR CARCINOMA.Semantic proximity
Outcome of living donor liver transplantation for Egyptian patients with hepatitis C (genotype 4)-related cirrhosis.Semantic proximity
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.Semantic proximity
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.Semantic proximity
Recurrence of hepatitis C virus (genotype 4) infection after living-donor liver transplant in Egyptian patients.Semantic proximity
Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.Semantic proximity
Risk of hepatocellular carcinoma development in cases of hepatitis C treated by long-term, low-dose PEG-IFNα-2a.Semantic proximity
Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis.Semantic proximity
Prognosis in liver transplantation recipients after hepatitis B virus recurrence.Semantic proximity
Select a neighboring publication to make it the new centre.